Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Eur J Pharm Sci. 2015 Aug 19;80:43–52. doi: 10.1016/j.ejps.2015.08.008

Table I.

Formulation processing conditions.

Formulation Polymer carbamazepine
% (w/w)
Polymer
%(w/w)
Vent
port
Torque% Pressure
(Bar)
Moisture Content
%
Drug Content
%
Screw
speed
(rpm)
Temperature
(°C)
A0 Kollidon® 17 PF 25 75 None 19.89 (7.48) 2.35 (2.31) 6.21 (1.28) 91.79 (6.84) 100 145
A1 Kollidon® 17 PF 25 75 Zone 4 25.52 (6.02) 2.47 (0.03) 2.48 (0.74) 94.84 (4.99) 100 145
A2 Kollidon® 17 PF 25 75 Zone 6 23.91 (2.69) 2.52 (0.00) 1.02 (0.84) 99.38 (3.65) 100 145
A3 Kollidon® 17 PF 25 75 Zone 9 20.40 (1.38) 2.01 (0.00) 0.73 (0.21) 102.72 (2.47) 100 145
A-PM Kollidon®17 PF 25 75 NA NA NA 7.64 (0.92) 101.31 (2.61) NA NA
D0 Klucel ELF 25 75 None 46.61 (4.22) 2 (0) 3.32 (2.4) 91.41 (1.9) 100 140
D1 Klucel ELF 25 75 Zone 4 73.59 (2.30) 2 (0) 2.71 (2.08) 93.14 (1.51) 100 140
D2 Klucel ELF 25 75 Zone 6 73.76 (1.67) 2 (0) 2.34 (1.29) 95.41 (1.44) 100 140
D3 Klucel ELF 25 75 Zone 9 55.95 (1.56) 2 (0) 1.8 (0.89) 99.05 (1.12) 100 140
D-PM Klucel ELF 25 75 NA NA NA 3.45 (0.77) 99.64 (1.72) NA NA

Parentheses represent relative standard deviation, PM- physical mixture.